Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy

Cancer Research

Volumn 70, Issue 13, 2010, Pages 5326-5336

  Sato, Nagato ^a,b   Yamabuki, Takumi ^a   Takano, Atsushi ^a,e   Koinuma, Junkichi ^a   Aragaki, Masato ^a   Masuda, Ken ^a   Ishikawa, Nobuhisa ^a   Kohno, Nobuoki ^c   Ito, Hiroyuki ^d   Miyamoto, Masaki ^b   Nakayama, Haruhiko ^d   Miyagi, Yohei ^d   Tsuchiya, Eiju ^d   Kondo, Satoshi ^b   Nakamura, Yusuke ^a   Daigo, Yataro ^a,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DICKKOPF 1 PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CANCER; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; SEROLOGY; STOMACH CANCER; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, NEUTRALIZING; CASE-CONTROL STUDIES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEOPLASMS; NIH 3T3 CELLS; TUMOR MARKERS, BIOLOGICAL; WNT PROTEINS;

EID: 77954374183     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3879     Document Type: Article

References (50)

1. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-27.
2. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
3. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-89.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. (Pubitemid 44917502)
5. Daigo Y, Nakamura Y. From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg 2008;56:43-53. (Pubitemid 351311467)
6. Kikuchi T, Daigo Y, Katagiri T, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003;22:2192-205.
7. Kakiuchi S, Daigo Y, Tsunoda T, Yano S, Sone S, Nakamura Y. Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice. Mol Cancer Res 2003;1:485-99.
8. Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004;13:3029-43.
9. Kikuchi T, Daigo Y, Ishikawa N, et al. Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol 2006;28:799-805.
10. Taniwaki M, Daigo Y, Ishikawa N, et al. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol 2006;29:567-75.
11. Yamabuki T, Daigo Y, Kato T, et al. Genome-wide gene expression profile analysis of esophageal squamous cell carcinomas. Int J Oncol 2006;28:1375-84.
12. Suzuki C, Daigo Y, Kikuchi T, Katagiri T, Nakamura Y. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res 2003;63:7038-41.
13. Kato T, Daigo Y, Hayama S, et al. A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis. Cancer Res 2005;65: 5638-46.
14. Furukawa C, Daigo Y, Ishikawa N, et al. Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. Cancer Res 2005;65:7102-10.
15. Suzuki C, Daigo Y, Ishikawa N, et al. ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res 2005;65:11314-25. (Pubitemid 41821688)
16. Ishikawa N, Daigo Y, Takano A, et al. Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Sci 2006;97:737-45. (Pubitemid 43983786)
17. Takahashi K, Furukawa C, Takano A, et al. The neuromedin u-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res 2006;66:9408-19. (Pubitemid 44623637)
18. Hayama S, Daigo Y, Kato T, et al. Activation of CDCA1-2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res 2006;66:10339-48. (Pubitemid 44799753)
19. Kato T, Hayama S, Yamabuki Y, et al. Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer. Clin Cancer Res 2007;13:434-42. (Pubitemid 46225347)
20. Suzuki C, Takahashi K, Hayama S, et al. Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer. Mol Cancer Ther 2007;6:542-51. (Pubitemid 46332456)
21. Hayama S, Daigo Y, Yamabuki T, et al. Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. Cancer Res 2007;67: 4113-22. (Pubitemid 46815056)
22. Taniwaki M, Takano A, Ishikawa N, et al. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res 2007;13:6624-31. (Pubitemid 350206797)
23. Mano Y, Takahashi K, Ishikawa N, et al. Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer. Cancer Sci 2007;98:1902-13. (Pubitemid 350002196)
24. Kato T, Sato N, Hayama S, et al. Activation of HJURP (Holliday junction-recognizing protein) involved in the chromosomal stability and immortality of cancer cells. Cancer Res 2007;67:8544-53. (Pubitemid 47437429)
25. Kato T, Sato N, Takano A, et al. Activation of placenta specific transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients. Clin Cancer Res 2008;14:2363-70. (Pubitemid 351551069)
26. Dunleavy EM, Roche D, Tagami H, et al. HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell 2009;137:485-97.
27. Hirata D, Yamabuki T, Ito T, et al. Involvement of epithelial cell transforming sequence 2 (ECT2) oncoantigen in lung and esophageal cancer progression. Clin Cancer Res 2009;15:256-66.
28. Sato N, Koinuma J, Fujita M, et al. Activation of WD repeat and HMG-box DNA binding protein 1 in pulmonary and esophageal carcinogenesis. Clin Cancer Res 2010;16:226-39.
29. Ishikawa N, Daigo Y, Yasui W, et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004;10: 8363-70. (Pubitemid 40053398)
30. Ishikawa N, Daigo Y, Takano A, et al. Increases of amphiregulin and transforming growth factor-á in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005;65:9176-84. (Pubitemid 41507981)
31. Yamabuki T, Takano A, Hayama S, et al. Dickkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007;67:2517-25.
32. Ishikawa N, Takano A, Yasui W, et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007;67:11601-11.
33. Takano A, Ishikawa N, Nishino R, et al. Identification of Nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 2009;69:6694-703.
34. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007;98:1803-8.
35. Mizukami Y, Kono K, Daigo Y, et al. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 2008;99:1448-54.
36. Kono K, Mizukami Y, Daigo Y, et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009;100:1502-9.
37. Glinka A, Wu W, Delius H, et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998;391:357-62.
38. Niida A, Hiroko T, Kasai M, et al. DKK1, a negative regulator of Wnt signaling, is a target of the β-catenin/TCF pathway. Oncogene 2004; 23:8520-6.
39. Semënov MV, Tamai K, Brott BK, et al. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol 2001;11:951-61.
40. Marvin MJ, Di Rocco G, Gardiner A, et al. Inhibition of Wnt activity induces heart formation from posterior mesoderm. Genes Dev 2001; 15:316-27.
41. Politou MC, Heath DJ, Rahemtulla A, et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006;119:1728-31.
42. Forget MA, Turcotte S, Beauseigle D, et al. The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer 2007;96:646-53.
43. Hall CL, Bafico A, Dai J, et al. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005; 65:7554-60.
44. Wirths O, Waha A, Weggen S, et al. Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. Lab Invest 2003;83:429-34.
45. Lee N, Smolarz AJ, Olson S, et al. A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer 2007;97:1552-9.
46. Yaccoby S, Ling W, Zhan F, et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007;109:2106-11.
47. Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009; 114:371-9.
48. Congy-Jolivet N, Probst A, Watier H, et al. Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Crit Rev Oncol Hematol 2007;64:226-33.
49. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 2006;25:7469-81.
50. Korol O, Gupta RW, Mercola M. A novel activity of the Dickkopf-1 amino terminal domain promotes axial and heart development independently of canonical Wnt inhibition. Dev Biol 2008;324:131-8.